Table 1.
Baseline characteristics of SARS-CoV-2 unexposed, but at T2 seroconverted persons / patients of the DIA-Vacc pure vaccination cohort.
| Variable | Category | MP | DP | KTR |
|---|---|---|---|---|
| Number | evaluable | 125 | 970 | 110 |
| Age (years) | mean ± SD | 47·8 ± 11·7 | 67·5 ± 13·9 | 57·6 ± 13 |
| Male Sex | n / % | 28 / 22·4 | 636 / 65·6 | 69 / 62·7 |
| BMI (kg/m2) | mean ± SD | 26·1 ± 5·1 | 27·8 ± 5·8 | 26·5 ± 4·7 |
| Cause of end stage renal disease | n / % | n.a. | 797 / 82·2 | 70 / 63·6 |
| Diabetes-Hypertension-Vascular disease | n / % | n.a. | 481 / 49·6 | 19 / 17·3 |
| Glomerulonephritis-Interstitial nephritis | n / % | n.a. | 206 / 21·2 | 27 / 24·5 |
| Vasculitis | n / % | n.a. | 24 / 2·5 | 2 / 1·8 |
| Polycystic kidney disease | n / % | n.a. | 86 / 8·9 | 22 / 20 |
| Unknown | n / % | n.a. | 173 / 17·8 | 40 / 36·4 |
| Drug treated comorbidities | n / % | 29 / 23·2 | 933 / 96·2 | 95 / 86·4 |
| Diabetes mellitus | n / % | 4 / 3·2 | 348 / 35·9 | 24 / 21·8 |
| Cardiovascular disease | n / % | 23 / 18·4 | 903 / 93·1 | 90 / 81·8 |
| Lung disease | n / % | 5 / 4 | 58 / 6 | 6 / 5·5 |
| Liver cirrhosis | n / % | 0 / 0 | 13 / 1·3 | 1 / 0·9 |
| Cancer | n / % | 0 / 0 | 38 / 3·9 | 5 / 4·5 |
| None | n / % | 96 / 76·8 | 37 / 3·8 | 15 / 13·6 |
| Type of dialysis | n.a. | 970 / 100 | n.a. | |
| Hemodialysis | n / % | n.a. | 929 / 95·8 | n.a. |
| Peritonealdialysis | n / % | n.a. | 41 / 4·2 | n.a. |
| Time on dialysis (years) | mean ± SD | n.a. | 5·8 ± 5·8 | 5·9 ± 5·9 |
| On transplant waiting list | n / % | n.a. | 118 / 12·2 | n.a. |
| Time on transplantation (years) | mean ± SD | n.a. | n.a. | 11·7 ± 7·8 |
| Previous transplantation | n / % | n.a. | 68 / 7 | 19 / 17·3 |
| Hepatitis B vaccination failure | n / % | 2 / 1·6 | 202 / 20·8 | 12 / 10·9 |
| Flu vaccination winter 2020/21 | n / % | 74 / 59·2 | 713 / 73·5 | 58 / 52· |
| On immunosuppressive therapy | n / % | 1 / 0·8 | 34 / 3·5 | 109 / 99·1 |
| Corticosteroids | n / % | 0 / 0 | 24 / 2·5 | 47 / 42·7 |
| Calcineurin-Inhibitor | n / % | 0 / 0 | 8 / 0·8 | 95 / 86·4 |
| MMF/MPA | n / % | 0 / 0 | 4 / 0·4 | 62 / 56·4 |
| mTOR-Inhibitor | n / % | 0 / 0 | 1 / 0·1 | 23 / 20·9 |
| Belatacept | n / % | 0 / 0 | 1 / 0·1 | 3 / 2·7 |
| T-cell depleting ab | n / % | 0 / 0 | 0 / 0 | 0 / 0 |
| B-cell depleting ab | n / % | 0 / 0 | 0 / 0 | 0 / 0 |
| Other | n / % | 1 / 0·8 | 3 / 0·3 | 4 / 3·6 |
| Type of vaccine | ||||
| BNT162b2 mRNA | n / % | 36 / 28·8 | 151 / 15·6 | 29 / 26·4 |
| mRNA-1273 | n / % | 89 / 71·2 | 819 / 84·4 | 81 / 73·6 |
For this evaluation all patients with asymptomatic* or documented symptomatic** COVID-19 disease before and during vaccination up to T3 (six months) were excluded. Hepatitis B vaccination failure definition - patients with unsuccessful vaccination after at least four attempts; MP = Medical Personnel; DP = Dialysis Patients; KTR = Kidney Transplant Recipient; MMF-MPA = mycophenolate mofetil or mycophenolic acid;
*Asymptomatic COVID-19 disease definition - neither knowledge nor symptoms of COVID-19 disease, but IgG-antibody reaction to nucleocapsid (T0, T1, T2, or T3) or to the Spike protein subunit S1 (only T0) of the SARS-CoV-2 virus is positive.
**Symptomatic COVID-19 disease definition - SARS-CoV-2 PCR positive patients with clinical symptoms.